Agency for Healthcare Research and Quality September 11, 2015 – Federal Register Recent Federal Regulation Documents
Results 1 - 3 of 3
Schedules of Controlled Substances: Removal of [123
With the issuance of this final rule, the Administrator of the Drug Enforcement Administration removes [\123\I]ioflupane from the schedules of the Controlled Substances Act. This action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after an opportunity for a hearing through formal rulemaking. Prior to the effective date of this rule, [\123\I]ioflupane was, by definition, a schedule II controlled substance because it is derived from cocaine via ecgonine, both of which are schedule II controlled substances. This action removes the regulatory controls and administrative, civil, and criminal sanctions applicable to controlled substances, including those specific to schedule II controlled substances, on persons who handle (manufacture, distribute, reverse distribute, dispense, conduct research, import, export, or conduct chemical analysis) or propose to handle [\123\I]ioflupane.
Agency Information Collection Activities; Proposed eCollection eComments Requested; Applications for Special Deputation
The Department of Justice (DOJ), U.S. Marshals Service (USMS), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. This proposed information collection was previously published in the Federal Register at 80 FR 39800, on July 10, 2015, allowing for a 60 day comment period.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.